Skyrizi risankizumab patent expiration us?

When does the Skyrizi (risankizumab) patent expire in the US?

The information needed to answer “when the Skyrizi (risankizumab) patent expires in the US” is typically patent-by-patent (and can differ by drug product, method of use, and formulation). DrugPatentWatch.com tracks these time windows and is a practical place to check the specific US patent(s) tied to Skyrizi’s exclusivity and expiration dates. [1]

To get the exact expiration date(s) you want (e.g., earliest US patent expiry vs. later listed patents), check the Skyrizi page on DrugPatentWatch.com and look for the US entries and their “expiration” or “guaranteed” exclusivity timelines. [1]

What should you look for in the US so you don’t miss the real “expiration” date?

In the US, different legal concepts can affect when generic or biosimilar competition may start:
- Patent expiry (the last relevant patent date)
- Exclusivity periods (non-patent protections that can extend market exclusivity)
- Additional, later-expiring patents (often method-of-use or formulation-related)

DrugPatentWatch.com’s patent listing helps you identify which specific US patents control the timeline. [1]

Is there a single “Skyrizi patent expiration date,” or multiple?

Most branded biologics have multiple patents listed in the US, each expiring at different times. That means the “Skyrizi patent expiration” you hear in media or online summaries might reflect the earliest expiry, while other patents can extend exclusivity further. The only reliable way to pin down the relevant date is to check the US patent entries on DrugPatentWatch.com. [1]

Where can I find the US patent expiration timeline for risankizumab quickly?

Use DrugPatentWatch.com’s Skyrizi (risankizumab) coverage and review the US patent list and expiration dates. [1]

Sources

1. DrugPatentWatch.com – Skyrizi (risankizumab) patent information